BriaCell Therapeutics Corp.BCTXNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank64
5Y CAGR-48.6%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
-48.6%/yr
Long-term compound
Percentile
P64
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 1.21% |
| Q3 2025 | -29.84% |
| Q2 2025 | 12.82% |
| Q1 2025 | -46.97% |
| Q4 2024 | 11.52% |
| Q3 2024 | 36.09% |
| Q2 2024 | 6.49% |
| Q1 2024 | -16.20% |
| Q4 2023 | -11.10% |
| Q3 2023 | -33.14% |
| Q2 2023 | -27.31% |
| Q1 2023 | 15.28% |
| Q4 2022 | -6.96% |
| Q3 2022 | -28.62% |
| Q2 2022 | -12.85% |
| Q1 2022 | -61.12% |
| Q4 2021 | -43.63% |
| Q3 2021 | 67.03% |
| Q2 2021 | -2488.49% |
| Q1 2021 | 49.77% |
| Q4 2020 | 33.62% |
| Q3 2020 | -0.03% |
| Q2 2020 | 62.67% |
| Q1 2020 | -21.44% |
| Q4 2019 | 9.98% |
| Q3 2019 | -14.85% |
| Q2 2019 | 16.52% |
| Q1 2019 | -39.55% |
| Q4 2018 | 33.15% |
| Q3 2018 | -34.46% |
| Q2 2018 | -43.31% |
| Q1 2018 | -55.45% |
| Q4 2017 | 44.82% |
| Q3 2017 | 0.65% |
| Q2 2017 | -163.88% |
| Q1 2017 | -1.76% |
| Q4 2016 | -26.04% |
| Q3 2016 | -0.67% |
| Q2 2016 | 68.24% |
| Q1 2016 | -245.81% |